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FKBPL and its peptide derivatives inhibit
endocrine therapy resistant cancer stem
cells and breast cancer metastasis by
downregulating DLL4 and Notch4
Lana McClements1,2,3, Stephanie Annett2,4, Anita Yakkundi2, Martin O’Rourke2,5, Andrea Valentine2,5,
Nermeen Moustafa2, Abdelrahim Alqudah1,6, Bruno M. Simões7, Fiona Furlong2, Amy Short2, Stuart A. McIntosh8,
Helen O. McCarthy2, Robert B. Clarke7 and Tracy Robson2,4*
Abstract
Background: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in
both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more
aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated
in treatment resistance, recurrence and the development of metastatic disease.
Methods: In this study, we utilised in vitro, in vivo and ex vivo breast cancer models using ER+ MCF-7 and ER-
MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL
and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The
effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with
Dunnett’s multiple comparison test.
Results: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-
clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in
a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via
modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative
MDA-MB-231 breast cancer cell migration (n≥ 3, p < 0.05) and invasion (n≥ 3, p < 0.001) and this was translated in vivo
where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p < 0.05). In ER+ MCF-7 cells
and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant
mammospheres, representative of CSC content (n ≥ 3, p < 0.05). Whilst an in vivo limiting dilution assay, using
SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying
tumour recurrence by 12 (p < 0.05) or 21 days (p < 0.001), respectively, by reducing the number of CSCs. The
potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4.
Conclusion: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer
therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine
therapy resistant CSCs; both areas of unmet clinical need.
Keywords: Metastasis, Triple negative breast cancer, Estrogen receptor, Endocrine therapy, Breast cancer stem
cells, FKBPL, ALM201, AD-01, Notch4, DLL4, Tamoxifen, Letrozole
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Background
Breast cancer is a highly heterogeneous disease with
subtypes based on hormone receptors, oestrogen or pro-
gesterone receptors (ER/PR) and HER2 overexpression.
More recently, gene expression profiling led to identifi-
cation of five main molecular subtypes of breast cancer:
HER2 overexpression (ER−/PR−/HER2+), basal-like (ER
−/PR−/HER2−/basal marker+), luminal A (ER+/PR
+/HER2−/KI67-), luminal B (ER+/PR+/HER2−/KI67+ or
ER+/PR+/HER2+/KI67+) and normal-like (ER+/PR
+/HER2−/KI67-) [1]. Further subtypes have also been
identified based on integrative analysis of gene expres-
sion and copy number, suggesting increased complexity
of breast cancer heterogeneity [2]. Despite major break-
throughs in the treatment of breast cancer over the last
twenty years, there is still a significant number of pa-
tients who do not respond, develop resistance to ther-
apy, or experience tumour recurrence; late relapse in ER
+ breast cancer continues to be a particular issue. There
is now a plethora of evidence to suggest that cancer
stem cells (CSCs) are responsible for the incidence of
metastatic disease which is the main cause of death in
patients with breast cancer [3]. Triple negative breast
cancer or basal-like subtype constitutes around 20% of
breast cancer cases and it is highly metastatic with lim-
ited therapeutic options [4]. Chemotherapy remains the
only treatment option for this disease subtype. The
chemotherapy resistant CSC population has increased
metastatic potential in triple negative breast cancer
through activation of oncogenic pathways such as
STAT3, therefore there is an urgent need for new thera-
peutic options which target CSCs [5, 6]. On the other
hand, the most common type of breast cancer, ER+ (lu-
minal A/B or normal-like), is treated with endocrine
therapy in both the adjuvant and metastatic settings [7].
Tumour recurrence in endocrine-resistant breast cancer
patients leads to a more aggressive type of breast cancer
with enhanced metastatic ability [8]. In patients treated
with neoadjuvant letrozole, CD44+/CD24− mammosphere
forming cells, representative of CSCs, were increased and
the remaining tumour cells appeared to have a mesenchy-
mal phenotype consistent with the more aggressive,
basal-like type of breast cancer [9]. This acquired endo-
crine therapy resistance has been attributed to the activa-
tion of survival pathways such as the epidermal growth
factor receptor (EGFR) pathway and, more recently, the
Notch pathway [10]. The Notch 4 receptor, in particular,
regulates breast CSC activity [11] and it is also implicated
in endocrine therapy resistance in women treated with
tamoxifen [12, 13]. Furthermore, tumour and plasma
levels of the Notch 1, 2, or 4 receptors and DLL4 ligand
were positively correlated with nodal and distant metasta-
ses in breast cancer and shorter disease-free or overall sur-
vival compared to patients with high DLL4 levels [14, 15].
In relevant in vitro and in vivo cancer models, DLL4 has
also been implicated in chemoresistance [16], tumour
angiogenesis [17] and CSC activity [18]. Therefore, all of
these studies suggest that DLL4 and Notch 4 are viable
therapeutic targets for both triple negative and ER+ breast
cancer treatment.
FK506-binding protein like (FKBPL) is a novel
anti-tumour protein that belongs to the family of immu-
nophilins, but is a divergent member lacking peptidyl
prolyl isomerase activity [19]. Immunophilins orches-
trate protein-protein interactions therefore regulating
many cellular processes including cell signalling, differ-
entiation, cell cycle progression, metabolic activity and
apoptosis [20]. FKBPL has diverse anti-tumour roles
both as an intracellular and extracellular protein. Intra-
cellular FKBPL regulates ER signalling and, as such, has
prognostic value in terms of breast cancer survival. This
was demonstrated using publically available datasets [21]
and in a meta-analysis of five independent breast tissue
microarray (TMA) cohorts [21, 22]. In this cohort of
3277 patients, FKBPL was a significant and independent
predictor of breast cancer specific survival (BCSS), with
low FKBPL expression being associated with shorter
BCSS (HR = 1.31, 95% CI 1.15–1.50, p < 0.001). Likewise,
in a cohort of 2365 ER+ breast cancer patients, low
FKBPL expression had also a significantly shorter BCSS
compared to high FKBPL expression (HR = 1.34, 95% CI
1.13–1.58, p < 0.001) [21]. Similarly, RBCK1, an E3
ubiquitin-protein ligase, which regulates FKBPL levels,
also demonstrated a potential role as a prognostic and
predictive biomarker of response to endocrine therapy
in breast cancer patients in terms of BCSS [23].
In addition to this intracellular role, FKBPL’s extracel-
lular anti-angiogenic and anti-CSC roles were identified,
potentially through its ability to target CD44 [5, 24, 25].
Upregulation of CD44 is associated with angiogenesis,
stemness, tumourigenicity and cell migration [26]. The
‘first-in-class’ FKBPL-based peptides, AD-01 (24-amino
acid pre-clinical therapeutic candidate) and ALM201
(23-amino acid clinical therapeutic candidate which has
successfully completed a Phase Ia clinical trial [EudraCT
2014–001175-31]) [27], have also demonstrated strong
anti-angiogenic and anti-CSC effects [5, 24, 25]. The
anti-CSC activity of AD-01 led to downregulation of
stem cell markers, Nanog, Oct4 and Sox2 in breast can-
cer cell lines while the intratumoural knockdown of
FKBPL in a ZR-75 breast cancer xenograft mouse model
increased the expression of Nanog/, Oct4 and Sox2 [5];
Sox2 has been implicated in both metastasis and endo-
crine therapy resistance [28–30]. Therefore, since FKBPL
and its peptides have demonstrated inhibitory effects on
angiogenesis [24, 25], CSC signalling [5] and ER signal-
ling [21, 22], we hypothesised that FKBPL could also in-
hibit metastasis and endocrine therapy resistance driven
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by CSCs in breast cancer. Here, we show for the first
time, that FKBPL and its therapeutic peptides reduce
metastatic burden in a triple negative breast cancer
model and inhibit endocrine therapy resistant CSCs,
thereby reducing tumour initiation, in ER+ disease. Fur-
thermore, we elucidate additional targets of FKBPL such
as DLL4 and Notch 4, which in addition to CD44, are
potentially involved in the multiple anti-tumour effects
of FKBPL and its therapeutic peptide derivatives.
Methods
Cell culture
All cells were obtained from the American Type Culture
Collection, authenticated by short-tandem repeat (STR)
profiling carried out by the suppliers, and verified
as mycoplasma-free. MDA-MB-231 CD44 stable knock-
down (KD) cells were a gift from Prof. David Waugh
(QUB) [31]. The MCF-7 and MDA-MB-231 cell lines
were cultured in Dulbecco’s modified Eagle medium
(DMEM; Life Technologies, UK) supplemented with
10% foetal calf serum (FCS; GE Healthcare, UK). Cells
stably overexpressing FKBPL (D2 from parental cell line,
MCF-7, and A3 from parental cell line, MDA-MB-231)
were selected using 750 μg/mL G418 (Sigma, UK) and
grown in the presence of 375 μg/mL (3.1D2) or 750 μg/
mL (A3) G418 (Sigma, UK) as previously described [5].
Cell culture experiments were carried out at 37°C in a
humidified atmosphere of 95% O2/5% CO2.
Boyden chamber assays
A Boyden chamber assay was used to examine cell mi-
gration and invasion. MDA-MB-231 cells were treated
with AD-01 (1 nM) for 24 h. Following 24 h cells were
trypsinized and re-suspended, (1.0 × 104 cells in 200 μl
RPMI-1640 medium) and then placed into the uncoated
(for migration) or Matrigel coated (for invasion) upper
chambers (8-mm pore size; Millipore, USA). The lower
chambers were filled with 600 μl complete medium with
10% FBS. After incubation for 12 h at 37 °C,
non-invading cells were removed from the top of the
chamber with a cotton swab. The invaded cells on the
lower surface of the inserts were fixed and stained with
0.1% crystal violet, and five random fields for each insert
were counted at 200× magnification.
Primary samples
Solid breast tumour mastectomy samples or core biop-
sies treated in the neoadjuvant setting with letrozole
were collected from patients with fully informed consent
(NIB14–0117; Northern Ireland Biobank), cut into small
pieces (1 mm), and digested for 2 h on a rotating plat-
form in RPMI (Gibco, UK) containing 10% collagenase/
hyaluronidase (Stem Cell Technologies, UK). Following
tissue digestion, filtration through 70 μm and 40 μm cell
strainers (BD Technologies, UK) was carried out and
500 cancer cells per cm2 were seeded in the mammo-
sphere medium DMEM-F12 (Gibco, UK), containing
B27 minus vitamin A (Life Technologies, UK), 20 ng/ml
EGF (Roche, UK), PenStrep (Invitrogen, UK) ± ALM201
(100 nM) as previously described [5]. Frozen pleural ef-
fusion samples collected from the patients with meta-
static breast (n = 3) with fully informed consent
(COREC# 05/ Q1403/25 and 05/Q1403/159; Division of
Cancer Sciences, Manchester, United Kingdom) were
defrosted, cells counted and seeded in the mammo-
sphere assay for 72 h ± ALM201 (100 nM) as previously
described [5].
Treatments
1.2 × 104 MCF-7 cells were plated in a monolayer in
complete medium for 24 h. The medium was replaced
by DMEM-F12 containing 10% charcoal-stripped serum
medium and 17β-estradiol (100 nM; Sigma, UK) was
added to all wells except for the control well. Tamoxifen
(1 μM; Sigma, UK) and ALM201 (1 nM) were added
alone or in combination for 72 h and cells incubated at
37°C in a humidified atmosphere of 95% O2/5% CO2. In
a separate experiment, MCF-7 and MDA-MB-231 cell
monolayers were treated with AD-01 (100 nM) or
ALM201 (100 nM) before being used in mammosphere
assays, western blotting or quantitative real-time poly-
merase chain reaction (qRT-PCR).
Mammosphere assay
A single cell suspension was prepared following enzym-
atic (0.125% Trypsin-EDTA (Invitrogen, UK)) and man-
ual disaggregation and 500 cells/cm2 were seeded in low
adherent culture 6-well plates (VWR, UK) coated with
1.2% poly-HEMA (Sigma-Aldrich, UK) in mammosphere
medium at 37°C in a humidified atmosphere of 95% O2/
5% CO2 for 5–7 days as described previously [5].
Flow cytometry
MCF-7 and MDA-MB-231 were grown in a cell mono-
layer or as mammospheres for 72 h before cells were dis-
aggregated and incubated with pre-conjugated primary
antibodies BEREP4-FITC (1:10; Dako), CD44-APC (1:20;
BD Pharmigen), and CD24-PE (1:10; Beckman Coulter)
as previously described [11]. Fluorescence was measured
using BD FACSCanto II and analyzed by WinMDI 2.9.
Clonogenic assay
MCF-7, 3.1D2, MDA-MB-231 and A3 cells were plated
at a density of 50 or 100 cells/cm2 per well in a six well
plate containing DMEM + 10% FCS medium and incu-
bated for 10 days at 37°C in a humidified atmosphere of
95% O2/5% CO2. Following incubation the medium was
removed, colonies were fixed with 1% crystal violet/70%
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ethanol and holoclones/meroclones/paraclones counted
manually.
Western blotting
MDA-MB-231 or MCF-7 cells were treated with
ALM201 or AD-01 (100 nM) for 24 h before cells lysates
were prepared using Laemmli buffer (Sigma, UK) and
subjected to western blotting as reported previously [25].
Primary antibodies used included: DLL4 (Abcam, UK,
cat: ab7280; 1:500), Notch4-ICD (Abcam, UK,
cat:ab33163; 1:400), FKBPL (Proteintech, USA cat:
10060–1-AP; 1:1,000), CD44H (R&D Systems, USA, cat:
BBA10; 1:1,000), GAPDH (Sigma, UK; cat: G9545;
1:10,000). HRP-linked secondary antibodies were either
anti-mouse or anti-rabbit (GE Healthcare, UK; 1:10,000).
Densitometry was performed using ImageJ software
(NIH, USA) and adjusted to GAPDH.
Quantitative real-time PCR
Following treatment of the adherent cells, as described
above, RNA was extracted using GeneJET RNA purifica-
tion kit (Fisher Scientific, UK) according to manufac-
turer’s instructions and RNA was quantified using a
Nanodrop spectrophotometer (Thermo Fisher Scientific,
Basingstoke, UK). Complimentary DNA (cDNA) was
produced using Transcriptor first stand cDNA synthesis
kit (Roche, Herefordshire, UK) according to manufac-
turer’s instructions. qRT-PCR was performed using the
Lightcycler 480 PCR machine (Roche, UK). All Taqman
primer probe sets were supplied by Roche (DLL4,
cat:100073803; GAPDH, cat: 100065048; β-Actin, cat:
100063228).
In vivo lung metastasis assay
In one set of experiment, 8–12 week old in-house bred
female SCID mice (C.B-17/IcrHsd-PrkdcscidLystbg) were
selected at random and pre-treated subcutaneously (s/c)
once daily (a.m.) with AD-01 (0.003 or 0.3 mg/kg/day, n
= 5) or PBS (n = 6) for one week prior to injection with
5 × 105 MDA-MB-231-lucD3H1 cells, followed by con-
tinuation of treatment with AD-01 or PBS for a further
28 days. Lung cell load was assessed following i.p. injec-
tion of luciferin (150 mg/kg) on day 0 when mice were
inoculated with cells, then lung metastatic colonization
was assessed at day 28,), using non-invasive biolumines-
cence of total photon flux. In the second experiment,
MDA-MB-231-LucD3H1 cells were grown in a mono-
layer and treated with AD-01 (1 nM) for 1 day before 8–
12 week old female SCID mice were inoculated intraven-
ously with 4 × 105 pre-treated or mock (PBS) treated
MDA-MB-231-LucD3H1 cells. Following inoculation,
mice with detectable lung metastasis deposits were
treated with control (PBS, n = 5) or AD-01 (0.3 mg/kg/
day, n = 5 and 0.003 mg/kg/day, n = 5) for 26 days via i.p.
injection. On day 26, primary experimental outcome i.e.
lung metastatic colonization was assessed using
non-invasive bioluminescence of total photon flux. At
the end of the experiment, mice were euthanized by
the carbon dioxide method. One-way ANOVA with
post-hoc Dunnett’s multiple comparisons statistical test
was used to compare the metastatic burden between
control and the two treatment mice groups. All animals
were of a similar weight (approx. 20 g) at the start of the
experiments; weight and animal wellbeing was moni-
tored at least twice weekly. Mice were housed in a group
of up to 5 per cage in special SPF cages which included
autoclaved bedding material. All in vivo procedures were
carried out at the Biological Resource Unit at Queen’s
University Belfast.
Limiting dilution in vivo assay
MCF-7 cells (5 × 106) were implanted intradermally into
8–12 week old in-house bred female SCID mice bearing
oestrogen pellets (0.25 mg). Once MCF-7 xenografts
were established (100–150 mm3), the following treat-
ments were administered to randomly selected mice
once daily (a.m.): 1) vehicle control via oral gav-
age (100μl) and PBS s/c (100 μl; n = 6), 2) tamoxifen cit-
rate (Sigma, Cambridge, UK) via oral gavage (250 μg/
100 μl; n = 4), 3) ALM201 s/c (0.3 mg/kg/day; n = 4) and
4) tamoxifen citrate via oral gavage (250 μg/100 μl) and
ALM201 s/c (0.3 mg/kg/day; n = 4). The treatments were
administered for the duration of 21 days and tumours
were measured every 3 days. Following three weeks of
treatment, mice were euthanized using the carbon diox-
ide method, tumours were excised, disaggregated and
used for ex vivo mammosphere assays or intradermal
re-implantation into secondary (untreated) female SCID
mice at 5 × 105 cell concentrations per mouse (control,
n = 16; tamoxifen only, n = 15; ALM201, n = 7; tamoxifen
plus ALM201, n = 6). The primary experimental out-
come, i.e. time taken for tumour initiation, was recorded.
The secondary experimental outcome was the number
of mammospheres formed from tumours ex vivo from
each group. One-way ANOVA with post-hoc Dunnett’s
multiple comparisons statistical test was used to com-
pare tumour initiation and mammosphere content be-
tween control and the three treatment groups.
Statistical analysis
Data presented are a mean of at least 3 independent ex-
periments ± SEM. Primary sample data are from one pa-
tient; statistics were performed on 3–6 replicates.
One-way ANOVA or t-test were used to assess differ-
ences between control and treatment groups. For mul-
tiple comparisons post-hoc Dunnett’s multiple
comparison test was used. Statistical significance was
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determined by the P values less or equal to 0.05; *,
P < 0.05; **, P < 0.01; ***, P < 0.001.
Results
FKBPL and its therapeutic peptides target CSCs and
downregulate DLL4 and Notch4 in MDA-MB-231 and
MCF-7 cells
We have already demonstrated that FKBPL and its pep-
tide derivatives potentially exert their activity by target-
ing the CD44 pathway [5, 24]. Nevertheless, when we
treated MDA-MB-231 cells with a gamma-secretase in-
hibitor which inhibits the Notch pathway in combin-
ation with AD-01, an additive inhibitory effect on the
CSCs was observed [5]. Therefore, we investigated the
impact of AD-01, as well as endogenous FKBPL, using
cells stably overexpressing FKBPL (A3), on DLL4 and
Notch 4 levels, which are implicated in metastasis and
CSC fate [11, 14]. When we stably overexpress FKBPL
in MDA-MB-231 cells, the number of holoclones, which
represent CD44+ CSCs [32], were reduced by over 50%
(Fig. 1a, p < 0.001, picture 1 inset), whilst the number of
meroclones and paraclones, representing differentiated
cells [5], concomitantly increased (Fig. 1b, p < 0.001; pic-
ture 2 and 3 inset). Overall the number of colonies was
unaffected. FKBPL stable overexpression in
MDA-MB-231 cells also led to down-regulation of DLL4
protein (Fig. 1c, p < 0.01) and mRNA levels (Fig. 1d, p <
0.01). Similarly, treatment of MDA-MB-231 cells with
A
C D
B
Fig. 1 FKBPL overexpression induces differentiation of CSC-like colonies and downregulates DLL4 expression in MDA-MB-231 cells. A reduction in
the number of holoclones (a) and a concomitant increase in the number of meroclones and paraclones (b) was observed, using MDA-MB-231
cells with stable FKBPL overexpression (A3), vs. MDA-MB-231 controls. 50 or 100 cells/cm2 per well were seeded in a six-well plate containing
DMEM + 10% FCS medium and incubated for 10 days at 37°C in a humidified atmosphere of 95% O2/5% CO2 before colonies were counted
manually. (representative images in the inset; 1 – holoclones; 2 – meroclones; 3- paraclones). c Western blot of cell lysates collected from A3 or
MDA-231 cells were probed for DLL4, FKBPL and GAPDH (representative blot in inset). Protein expression was quantified using ImageJ, adjusted
to GAPDH and normalised to control. d Real-time qPCR analysis of DLL4 mRNA levels in MDA-MB-231 vs. A3 cells. The difference in gene
expression was presented as a fold change relative to the expression of the housekeeping genes, GAPDH and ß –Actin. Data points are mean ±
SEM. n ≥ 3. * p < 0.05, ** p < 0.01, ***p < 0.01 (t-test)
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AD-01 (100 nM), demonstrated inhibitory effects on both
DLL4 protein (Fig. 2a, p < 0.05) and Notch 4 intracellular
domain (ICD) protein expression (Fig. 2b, p < 0.05). Treat-
ment with the clinical peptide, ALM201 (100 nM), also
led to downregulation of DLL4 mRNA levels (Fig. 2c, p <
0.01). To elucidate whether the FKBPL-mediated effect on
mammosphere forming efficiency (MFE) was dependent
on CD44, ALM201 was used to treat MDA-MB-231
mammospheres with stable CD44 knockdown. To
demonstrate that MDA-MB-231 mammospheres were
representative of CSCs, a 10-fold enrichment in the
ESA+/CD44+/CD24- subpopulation was observed using
flow cytometry within MDA-MB-231 mammospheres
(Additional file 1: Figure S1). ALM201 was still able to in-
hibit the MFE in MDA-MB-231 CD44 knockdown cells at
a similar level to parental MDA-MB-231 cells (Fig. 2d, p <
0.01). No difference was observed between ALM201
treated cells with stable CD44 knockdown versus
ALM201 treated parental cells (MDA-MB-231; Fig. 2d).
This data suggests that ALM201 is not completely
dependent on CD44 for its anti-CSC activity, implicating
the involvement of DLL4 and Notch4, as demonstrated
above.
In ER+ breast cancer, we have shown that FKBPL is in
a HSP90-associated chaperone complex with ERα recep-
tor and that it can regulate ER signalling [22]. Using the
ER+ MCF-7 cell line, FKBPL overexpression led to a bet-
ter response to endocrine therapy i.e. tamoxifen and ful-
vestrant, whereas FKBPL knockdown had the opposite
effect [22]. Endocrine therapy resistance is associated
A B
C D
Fig. 2 Treatment with AD-01 or ALM201 downregulates DLL4 and/or Notch 4 expression. The anti-CSC effect of ALM201 appears independent of
CD44. Western blot of cell lysate from MDA-MB-231 cells treated with AD-01 (100 nM) and probed for DLL4 (a), Notch4ICD (b), and GAPDH
(representative blot in inset; Notch4ICD as double band). Relative protein expression was quantified using ImageJ (t-test). c Real-time qPCR
analysis of DLL4 mRNA levels in MDA-MB-231 cells treated with ALM201 (100 nM). The difference in gene expression was presented as a fold
change relative to the expression of the housekeeping genes, GAPDH and ß –Actin (t-test). d Mammosphere formation in stable CD44
knockdown (KD) MDA-MB-231 cells treated with ALM201 (100 nM) vs. parental (MDA-MB-231) cells (one-way ANOVA with post-hoc Dunnett’s
multiple comparisons test). Real-time qPCR analysis of CD44 mRNA levels in stable CD44 KD MDA-MB-231 cells vs. parental control; n = 1. Data
points are mean ± SEM. n ≥ 3. * p < 0.05, ** p < 0.01, ***p < 0.01. ICD – intracellular domain
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with an increase in the number of CSCs through activa-
tion of the Notch pathway [13, 33]. Here, we expand on
the role of FKBPL in ER+ breast cancer by investigating
the effect of stable FKBPL overexpression in MCF-7 cells
(D2) on CSC-like colonies, holoclones. Similar to the
triple negative breast cancer cell line, MDA-MB-231,
FKBPL overexpression in MCF-7 cells resulted in a re-
duction in the number of holoclones and concomitant
increase in the number of differentiated colonies while
the overall colony number remained the same (Fig. 3a,
p < 0.001). The effect of FKBPL stable overexpression in
MCF-7 cells on DLL4 was dramatic, showing over 90%
reduction in DLL4 protein expression (Fig. 3b, p < 0.001)
and a trend towards a reduction in DLL4 mRNA levels
(Fig. 3c, p = 0.057). In support of this, treatment of
MCF-7 cells with FKBPL’s peptide derivative, AD-01,
also led to downregulation of both DLL4 (p < 0.01) and
the Notch4 ICD (p < 0.05) proteins levels (Fig. 3d). Simi-
larly, the clinical peptide, ALM201, also showed down-
regulation of DLL4 mRNA levels in MCF-7 cells
(Fig. 4e, p < 0.001).
AD-01 inhibits migration, invasion and lung metastasis in
triple negative MDA-MB-231 experimental models
Based on our previously published work we have estab-
lished that the FKBPL pre-clinical peptide, AD-01, could
inhibit both endothelial and tumour cell migration in a
CD44-dependent manner [24, 25]. Furthermore, we have
demonstrated that AD-01 could target CSCs in the triple
negative MDA-MB-231 cell line [5]. Since CSCs are
A
C D E
B
Fig. 3 FKBPL overexpression induces differentiation of stem cell-like holoclones to more differentiated meroclones/paraclones in MCF-7. FKBPL
overexpression or AD-01/ALM201 treatment downregulates DLL4 and Notch4 ICD expression in MCF-7 cells. a A reduction in the number of
holoclones formed and a concomitant increase in the number of more differentiated, meroclone and paraclone colonies, following stable FKBPL
overexpression (D2), was observed in MCF-7. b Western blot of cell lysates from MDA-MB-231 cells stably overexpressing FKBPL (A3) probed for
DLL4, FKBPL and GAPDH (representative blot in inset). c Real-time qPCR analysis of DLL4 mRNA levels in MCF-7 vs. D2 cells. d Western blot of cell
lysate from MCF-7 cells treated with AD-01 (100 nM) and probed for DLL4, Notch4ICD (double band) and GAPDH (representative blot in inset).
Relative protein expression was quantified using ImageJ. e Real-time qPCR analysis of DLL4 mRNA levels in MCF-7 cells treated with ALM201 (100
nM). The difference in gene expression was presented as a fold change relative to the expression of the housekeeping genes, GAPDH and ß –
Actin. Data points are mean ± SEM. n ≥ 3. * p < 0.05, ** p < 0.01, ***p < 0.01 (t-test). ICD – intracellular domain
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known to be associated with invasion and metastasis, here
we addressed whether the FKBPL-peptide could inhibit
invasion in vitro and whether this could be translated in
an experimental model of metastasis using the triple nega-
tive metastatic MDA-MB-231 breast cancer cells. Treat-
ment of MDA-MB-231 cells for 24 h with AD-01 (1 nM)
confirmed inhibition of cell migration, the first step in the
invasive process, through an uncoated Boyden chamber
(Fig. 4a, n ≥ 3, p < 0.01). Furthermore, we were also able to
prevent invasion through a Matrigel coated Boyden
chamber (Fig. 4b, n ≥ 3, p < 0.001). Since it has been previ-
ously demonstrated by Ebos and colleagues [34] that
anti-angiogenic agents can promote metastases, we inves-
tigated whether AD-01 pre-treatment can prevent meta-
static invasion using two separate in vivo MDA-MB-231
experimental lung metastasis models. In the first experi-
ment, SCID mice were pre-treated daily with the stated
dose of AD-01 or PBS for 1 week prior to being inoc-
ulated with MDA-MB-231-lucD3H1 cells via tail vein
injection. AD-01 was subsequently administered to
mice daily via i.p. injection (0.03 and 0.3 mg/kg/day).
Control mice received PBS injections daily. AD-01
(0.3 mg/kg/day, p < 0.05; 0.003 mg/kg/day, p = 0.08)
inhibited lung colonization of breast cancer cells
A
C
D
B
Fig. 4 AD-01 inhibits MDA-MB-231 cell migration and invasion, and metastatic load in MDA-MB-231 mouse model of lung metastasis in SCID
mice. MDA-MB-231 cell migration (a) and invasion (b) were assessed following 24 h treatment with AD-01 (1 nM) using a Boyden chamber assay.
Data points are mean ± SEM. n ≥ 3. ** p < 0.01, ***p < 0.01 (t-test). c SCID mice were treated for 7 days with AD-01 or PBS before MDA-MB-231-
LucD3H1 cells were injected i.v. Control group received PBS i.p. daily (n = 6) whereas treatment groups received AD-01 i.p. 0.3 mg/kg/day (n = 5)
or 0.003 mg/kg/day (n = 5) for further 28 days. Lung metastasis colonization was assessed using non-invasive bioluminescence of total photon flux
at day 0 and 28. A representative bioluminescent image of lungs from each group is shown inset. d Lung metastasis colonization was assessed
using non-invasive bioluminescence of total photon flux at day 26 following inoculation of SCID mice with one million MDA-MB-231-LucD3H1
pre-treated with PBS or AD-01 (1 nM) for 1 day in vitro. Following inoculation and detection of lung metastatic load, AD-01 (0.3, n = 5 or 0.003
mg/kg/day; n = 5) or PBS (100 μl; n = 5) were administered i.p. daily for 26 days. Each mouse is plotted on the graph. Representative
bioluminescent images of lung metastatic load and other organs from each group are shown inset. * p < 0.05 (one-way ANOVA with post-hoc
Dunnett’s multiple comparisons test)
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following 28 days of in vivo treatment in addition to
pre-treatment in vitro (Fig. 4c). No difference in the
total photon flux was observed at day 0 following intraven-
ous inoculation of MDA-231-lucD3H1 cells from either of
the pre-treated groups (PBS or AD-01; Fig. 4c). In the sec-
ond experiment, MDA-MB-231-lucD3H1 cells were pre-
treated for 24 h with the stated dose of AD-01 or PBS, and
injected via tail vein (in this experiment the mice were not
pre-treated). Following i.v. injection of the cells, mice were
treated i.p. in vivo for 26 days using either PBS as a control
or AD-01 (0.3 or 0.003mg/kg/day). Lung metastasis
colonization was assessed using non-invasive biolu-
minescence of total photon flux. AD-01 (0.003mg/kg/day;
p < 0.05) treatment significantly reduced the total photon
flux, indicative of the lung cell load compared to the vehicle
PBS control (Fig. 4d, p < 0.05). Weight and wellbeing
of each mouse was monitored daily and no significant
weight reduction (≥15%) was observed. The drug was
generally well tolerated and all animals where initial
metastatic burden was recorded following MDA-MB-
231-lucD3H1 cell inoculation via tail vein were
included in the analysis.
FKBPL and its therapeutic peptides target endocrine
therapy-resistant CSCs within an ER+ breast cancer
context in both cell lines and clinical samples
CSCs within ER+ breast cancer are resistant to endo-
crine therapy due to the lack of ER expression [35]. In
order to demonstrate that FKBPL-based clinical peptide,
ALM201, is able to target endocrine therapy resistant
CSCs in ER+ breast cancer, we treated the ER+ breast
cancer cell line, MCF-7, with estradiol (100 nM) ± tam-
oxifen (1 μM) ± ALM201 (1 nM) and carried out mam-
mosphere assay. A trend towards increase in the MFE
was demonstrated following treatment with tamoxifen
alone (MFE = 3.5%, p = 0.17) in the presence of estradiol
(Fig. 5a). ALM201 alone, at a very low dose (1 nM)
(MFE = 2.2%, p = 0.08) or in combination with tamoxifen
(MFE = 1.86%, p < 0.01) reduced the MFE compared to
estradiol treatment alone (Fig. 5a); the statistical signifi-
cance was only observed when tamoxifen and ALM201
were used in combination. Importantly, the combination
of ALM201 and tamoxifen seems to be even more ef-
fective at inhibiting the MFE (%). To ensure that mam-
mospheres were representative of the CSC population,
we were able to demonstrate a two-fold enrichment in
the CD44+/CD24− subpopulation of cells within MCF-7
mammospheres (Additional file 2: Figure S2).
Previously, using a range of ER+ and ER- metastatic
breast cancer patient samples we demonstrated a modest
20% reduction in the MFE following AD-01 treatment,
even though the dose of AD-01 used was low (5 nM) [5].
Here we assessed the effects of ALM201, at a dose of
100 nM using clinically relevant ER+ breast cancer tissue
from patients undergoing mastectomy and treated in the
neoadjuvant setting with letrozole. We demonstrated up
to 12-fold higher MFE (MFE ranged from 1.5–4.8; Fig.
5b- black bars) compared to our previously published
data using breast cancer tissue from patients without
neoadjuvant treatment (where MFEs of 0.4 were ob-
served) [5]. Importantly, in three of the four patient
samples, ALM201 significantly reduced the MFE, up to
70% (Fig. 5b). Sample 029AF, where no significant effect
was observed, was negative for the expression of PR un-
like the rest of the samples which were all ER+ and PR+
(Additional file 3: Table S1).
The anti-CSC effect of ALM201 was further validated
in ER+ metastatic breast cancer samples from pleural ef-
fusions. ALM201 (100 nM) was effective at reducing the
MFE by over 45% in three patient samples (BB3EC66–
45% reduction; BB3RC8–66% reduction; BB3RC90–64%
reduction; p < 0.01 or 0.001; Fig. 5c). This is important,
since these samples are from patients with end-stage,
highly metastatic disease with treatment-resistant tu-
mours; all of these patients were unsuccessfully treated
with a wide range of endocrine and chemotherapy regi-
mens (Additional file 4: Table S2).
ALM201 in combination with tamoxifen delays tumour
initiation and reduces the number of mammosphere
forming tamoxifen-resistant CSCs in ER+ MCF-7
xenografts
In order to validate the results obtained in vitro and in
clinical samples, an in vivo tumour initiation assay was
carried out. Here, mice carrying established tumours
(100–150 mm3) were treated with 1) vehicle control, 2)
tamoxifen (12.5 mg/kg/day), 3) ALM201 (0.3 mg/kg/
day), and 4) tamoxifen + ALM201, for a period of 21
days. Following three weeks of treatment, tumours were
excised and tumour cells used in an ex vivo mammo-
sphere assay or re-implanted into second generation
SCID mice without any further treatment to assess the
tumour initiating potential. The ex vivo mammosphere
assay, using tumour cells from first generation treated
MCF-7 xenografts, showed no change in the MFE be-
tween control and tamoxifen treated tumours (MFE =
3.5%, control (n = 6) vs. MFE =3.3%, tamoxifen (n = 4);
Fig. 6a). ALM201 alone or in combination with tamoxi-
fen led to a significant reduction in the MFE (MFE = 2%,
ALM201 (n = 4), p < 0.01; and MFE = 0.5%, ALM201 and
tamoxifen (n = 4), p < 0.001; Fig. 6a) compared to tam-
oxifen treatment. Interestingly, the combination of tam-
oxifen and ALM201 appeared even more effective at
inhibiting the MFE than ALM201 alone (Fig. 6a, p <
0.01). When tumour cells were re-implanted into the
second generation untreated mice, there was no delay in
the number of days to palpable tumours between
vehicle-treated or tamoxifen-treated tumour cells (Fig.
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6b), suggesting that tamoxifen does not target the
tumour initiating cell population. However, cells derived
from the first generation ALM201-treated mice showed
a significant delay in tumour recurrence of ~ 12 days
compared to control or tamoxifen (Fig. 6b, p < 0.05). Im-
portantly, the time to palpable tumour was even further
delayed by 22 days when cells from the first generation
tamoxifen and ALM201 treated mice were used in com-
bination compared to tamoxifen alone (Fig. 6b, p <
0.001). Weight and wellbeing of each mouse were moni-
tored closely and no significant weight reductions
(≥15%) were observed. Any mouse showing signs of poor
wellbeing was euthanized according to the approved
protocol. The drugs was generally well tolerated and all
animals displaying tumours were included in the ana-
lysis; vehicle-treated/control (13/16), tamoxifen (14/15),
ALM201 (5/7) and tamoxifen+ALM201 (5/6).
When secondary tumours were excised and tumour
cells were subjected to an ex vivo mammosphere
assay, no effect on the MFE was observed in the
tamoxifen-treated group (n = 4, p = 0.1) compared to
control (n = 6; Fig. 6c). However, in combination
with ALM201, the MFE appeared reduced compared
to tamoxifen alone (n = 3; Fig. 6c, p = 0.15), however
not statistically significant. Treatment with ALM201
alone did not lead to any significant change in the
MFE compared to control (n = 2; Fig. 6c). This could
be due to the small number of tumours excised or
interrupted treatment with ALM201 in the second
generation mice. Interestingly, ex vivo qPCR analysis
of MCF-7 xenografts treated with both ALM201 and
tamoxifen also showed a trend towards downregula-
tion of DLL4 mRNA compared to control (Fig. 6d;
n = 2).
A
B C
Fig. 5 Tamoxifen shows no effect on the number of mammospheres formed whereas ALM201 alone or in combination with tamoxifen reduces
the number of mammosphere in MCF-7 cells and patient samples. a MCF-7 cells were treated with estradiol (100 nM; E2) ± tamoxifen (1 μM;
Tam) ± ALM201 (1 nM) in a monolayer for 72 h before the cells were used in the mammosphere assay. Mammospheres formed were counted
manually 3–5 days later (one-way ANOVA with post-hoc Dunnett’s multiple comparisons test). b Mammospheres formed from cancer cells
derived from individual primary breast cancer sample treated neoadjuvantly with letrozole were counted in vitro following treatment with
ALM201 (100 nM) or control for 5–7 days; n ≥ 5 replicates (t-test). c Mammospheres formed from cancer cells derived from pleural effusions from
individual breast cancer patients (ER+ metastatic breast cancer samples) were counted following treatment with ALM201 (100 nM) or control for
7 days; n ≥ 5 replicates (t-test). Data points are mean ± SEM. n ≥ 3. * p < 0.05, ** p < 0.01, *** p < 0.001
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Discussion
We have previously demonstrated a role for FKBPL in
ER signalling, endocrine therapy response, angiogenesis
and CSC differentiation [5, 22, 24]. To date, the mechan-
ism of action has been attributed to a potential role in
the CD44 pathway and stabilisation of p21 [5, 22, 36]. In
addition to this, we have shown that high FKBPL levels
are associated with a positive prognosis in breast cancer
[21]. In this study, for the first time, we assessed the
pre-clinical activity of novel systemic anti-cancer thera-
peutic peptides, ALM201 & AD-01, in the metastatic
setting, and highlighted their impact on endocrine ther-
apy resistant cancer stem cells; both areas of unmet clin-
ical need. These effects were demonstrated using a range
of experiments with cell lines, primary breast cancer
samples and in vivo models.
In triple negative breast cancer using MDA-MB-231 cells,
we demonstrated FKBPL-mediated differentiation of CSCs
to more “mature” cancer cells, no cytotoxic effect and in-
hibition of cell migration, invasion and metastasis. In our in
vivo lung metastasis model we demonstrated that
pre-treatment with AD-01 prevents lung colonization of
breast cancer cells which is, likely, through prevention of
engraftment of the tumour cells given AD-01’s inhibitory
effect on cell migration and invasion. In ER+ breast cancer,
using MCF-7 cells and ER+ breast cancer samples, we also
demonstrated FKBPL-mediated CSC differentiation, inhib-
ition of CSCs resistant to endocrine therapy and delay in
A B
C D
Fig. 6 ALM201 alone or in combination with tamoxifen delays tumour recurrence in vivo which correlates with reduced number of
mammospheres ex vivo. a Established MCF-7 xenografts (100–150mm3) were treated with vehicle control (n = 5), tamoxifen (n = 4) or ALM201 (n
= 4) alone or in combination (n = 4) for 21 days. Mammosphere formation was assessed ex vivo following excision and disaggregation of
established MCF-7 xenografts; n ≥ 3 replicates per mouse. b Tumour cells from the treated xenografts were re-implanted into secondary mice
and tumour occurrence was monitored twice a week and time to tumour initiation calculated (vehicle control, n = 13; tamoxifen (Tam), n = 14;
ALM201, n = 5; tamoxifen + ALM201 (Tam + ALM201), n = 5). c Mammosphere formation following excision and disaggregation of established
MCF-7 xenografts from the second generation mice without any further treatment in vivo (control, n = 6; Tam, n = 4; ALM201, n = 2; Tam +
ALM201, n = 3); n ≥ 3 replicates per mouse. d Real-time qPCR analysis of DLL4 in MCF-7 xenografts treated with tamoxifen and ALM201 in vivo (n
= 2). The difference in gene expression was presented as a fold change relative to the expression of the housekeeping genes, GAPDH and ß
-Actin. Data points are mean ± SEM. n ≥ 3. * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc Dunnett’s multiple
comparisons test)
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tumour initiation. Interestingly, ALM201 in combination
with tamoxifen appeared even more effective at inhibiting
CSC population than ALM201 alone while tamoxifen
shows no effect on CSCs. Furthermore, FKBPL appears to
downregulate DLL4 and Notch 4 levels, which has not been
previously reported. Therefore, we identified a novel role
for FKBPL in reducing the metastatic burden which could
be linked to the inhibition of CSCs and the regulation of
CD44, DLL4 and Notch 4. This is very important since
other anti-angiogenic agents show increased metastatic po-
tential [34]. CSCs have been implicated in cancer metasta-
ses, as the primary cells likely to migrate and populate
metastatic sites, due to their strong migratory and pluripo-
tent potential [37]. High Notch activity has been implicated
in cancer pathogenesis and Notch 4 is specifically active
within breast CSCs [11, 38]. Moreover, both Notch and
CD44 have been implicated in hypoxia-driven enrichment
of CSC population, tumour recurrence and enhanced meta-
static phenotype after treatment with anti-angiogenic
agents or hypoxia inducible factors [39–41]. Our data sug-
gests that FKBPL-based peptides in addition to their
well-established anti-angiogenic [24, 25] and anti-CSC ac-
tivity [5] via CD44, are able to inhibit lung metastasis, pos-
sibly by modulating the Notch pathway members, DLL4
and Notch 4, within breast cancer, giving these agents a po-
tential competitive advantage. Further studies would be re-
quired to elucidate the role of FKBPL/ALM201/AD-01 in
Notch 4 and DLL4 signalling.
Furthermore, our in vivo data in relation to tamoxifen
treatment confirms that tamoxifen does not target CSCs
or inhibit tumour initiation. Conversely, ALM201 alone
or in combination with tamoxifen demonstrated a sub-
stantial delay in tumour initiation and reduced the pro-
portion of the CSC-like population assessed by ex vivo
mammosphere assay, which correlates with the content
of CD44+/CD24− CSC population. The combination of
tamoxifen and ALM201 had a more pronounced inhibi-
tory effect on tumour initiation and the CSC-like popu-
lation compared to ALM201 alone, thus suggesting that
this combination might be advantageous clinically.
Notch inhibitors have already demonstrated activity in
combination with tamoxifen, and Notch 4, in particular,
has been implicated as a viable target to prevent metas-
tasis in tamoxifen-resistance breast cancer [42, 43].
Nevertheless, correlation between the activity of Notch
ligands, receptors and target genes is complex and eluci-
dating the functional role for individual Notch receptors
and ligands in mediating resistance to therapy, tumour
recurrence or metastasis in breast cancer is necessary
[44, 45]. Our data suggests that FKBPL can specifically
downregulate DLL4 and intracellular Notch 4, however
the effects on other important members of the Notch
pathways and Notch signalling needs to be investigated
further.
In summary, based on the results obtained in this study
and previously published studies, while the novel
FKBPL-based anti-cancer therapeutic peptides, ALM201
and AD-01, are not cytotoxic, these agents have multiple
synergistic anti-tumour activities including anti-angiogenic,
anti-CSC and anti-metastatic involving CD44, and possibly,
DLL4 and Notch 4 which gives them a clinical advantage
over other anti-angiogenic agents.
Conclusions
FKBPL-derived therapeutic peptides, AD-01/ALM201,
demonstrate significant anti-angiogenic, anti-CSC activity
and, now, anti-metastatic activity and therefore have en-
hanced clinical utility in comparison to clinically available
anti-angiogenic agents. This triple therapeutic action will
undoubtedly provide added clinical benefit as it progresses
through clinical development. Based on robust pre-clinical
efficacy, without associated toxicity, ALM201 entered a
‘first in man’ clinical trial in oncology, where unlike other
anti-angiogenics, it is not cytotoxic and displayed an ex-
cellent safety profile in this Phase I clinical trial [27].
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